Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 5.52B | 5.32B | 5.28B | 5.40B | 4.94B |
Gross Profit | 1.69B | 1.64B | 1.63B | 1.63B | 1.41B |
EBITDA | 337.27M | 624.75M | 469.51M | 449.14M | 353.62M |
Net Income | -126.55M | 17.25M | 131.96M | 162.80M | 125.23M |
Balance Sheet | |||||
Total Assets | 10.79B | 11.25B | 11.27B | 11.73B | 11.98B |
Cash, Cash Equivalents and Short-Term Investments | 571.21M | 676.16M | 704.13M | 902.47M | 971.71M |
Total Debt | 6.10B | 5.93B | 5.95B | 6.21B | 6.19B |
Total Liabilities | 7.28B | 7.06B | 7.11B | 7.23B | 7.26B |
Stockholders Equity | 3.51B | 4.19B | 4.16B | 4.50B | 4.72B |
Cash Flow | |||||
Free Cash Flow | 154.06M | 222.35M | 146.69M | 206.33M | 151.12M |
Operating Cash Flow | 353.53M | 514.18M | 363.66M | 423.57M | 530.96M |
Investing Cash Flow | -96.64M | -67.96M | -22.12M | -257.88M | -457.31M |
Financing Cash Flow | -341.98M | -477.95M | -515.34M | -220.08M | 168.74M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | HK$10.10B | 275.73 | 4.16% | ― | 34.39% | ― | |
62 Neutral | HK$8.94B | ― | -3.29% | ― | 3.76% | -833.33% | |
56 Neutral | HK$10.18B | ― | -13.97% | ― | -97.81% | -117.20% | |
54 Neutral | HK$7.86B | 324.14 | 2.28% | ― | -57.55% | -87.49% | |
54 Neutral | HK$7.73B | ― | -8.04% | ― | 66.72% | 33.68% | |
51 Neutral | $7.35B | 0.50 | -65.61% | 2.47% | 15.28% | 1.44% |
CK Life Sciences International (Holdings) Inc. has issued a profit warning, indicating an expected loss of approximately HK$150 million for the first half of 2025, compared to a HK$1 million profit in the same period in 2024. This shift from profit to loss is primarily due to the company’s strategic decision to increase investments in research and development, while the overall operations remained stable. The final financial results are still being finalized and will be disclosed in the interim results announcement on 12 August 2025.
CK Life Sciences International (Holdings) Inc. has announced that its board of directors will meet on August 12, 2025, to approve the interim results for the first half of the year and consider the payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and potential returns for shareholders, impacting its market positioning and stakeholder interests.
CK Life Sciences International (Holdings) Inc. successfully conducted its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed with overwhelming support. The resolutions included the approval of the audited financial statements for 2024, the election of directors, the appointment of auditors, and the granting of mandates to issue and buy back shares. This outcome reinforces the company’s governance structure and operational strategy, potentially strengthening its market position and shareholder confidence.
CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Nomination Committee, which was established to ensure effective corporate governance in compliance with the Hong Kong Stock Exchange’s Listing Rules. The committee is responsible for reviewing the board’s structure and composition, identifying and recommending director candidates, assessing director independence, and supporting board performance evaluations. These measures are designed to align the board’s capabilities with the company’s strategic goals and enhance shareholder value.
CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Audit Committee, which plays a crucial role in overseeing the company’s financial reporting, risk management, and internal control systems. The Audit Committee is composed of non-executive directors, with a majority being independent, and is tasked with ensuring compliance with corporate governance standards. This announcement underscores the company’s commitment to maintaining robust governance practices, which is vital for stakeholder confidence and the company’s operational integrity.